Journal of Antimicrobial Chemotherapy, Vol 39, 51-55, Copyright © 1997 by The British Society for Antimicrobial Chemotherapy
KP Klugman and TD Gootz
Trovafloxacin had greater in-vitro activity than comparative
fluoroquinolone agents against penicillin-sensitive pneumococci in studies
from the USA, UK, Slovakia, Czech Republic, Sweden and South Africa. This
activity was maintained against penicillin-resistant strains, with MIC90
values of < or = 0.25 mg/L observed for both groups. Bactericidal
activity appeared to occur within one or two dilutions of the MIC and, in
the limited number of strains studied, the MIC was independent of the
medium tested and pH over the range pH 5-8. Mutation to decreased
susceptibility to trovafloxacin occurred in vitro at a low frequency in the
pneumococcus (< or = 8.9 x 10(-9)). Mutants with changes in the
topoisomerase IV A subunit (GrlA) were still inhibited by 0.5 mg/L of
trovafloxacin. Trovafloxacin was more efficacious than ciprofloxacin,
temafloxacin or ofloxacin in mouse pneumonia models for both
penicillin-susceptible and penicillin- resistant pneumococci. Trovafloxacin
was also highly efficacious in a rabbit pneumococcal meningitis model.
These data suggest that the clinical efficacy of trovafloxacin against
pneumococci should be evaluated further.
ORIGINAL ARTICLES
In-vitro and in-vivo activity of trovafloxacin against Streptococcus pneumoniae
Department of Medical Microbiology, South African Institute for Medical Research and University of the Witwatersrand, Johannesburg. 174klug@chiron.wits.ac.za
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  I. S. Barequet, P. Denton, G. J. Osterhout, S. Tuli, and T. P. O'Brien Treatment of Experimental Bacterial Keratitis With Topical Trovafloxacin Arch Ophthalmol, January 1, 2004; 122(1): 65 - 69. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. H. Williams Jr Fluoroquinolones for Respiratory Infections : Too Valuable To Overuse Chest, December 1, 2001; 120(6): 1771 - 1775. [Full Text] [PDF]
|
|
|
|
 |
|
 D. F. Sahm, D. E. Peterson, I. A. Critchley, and C. Thornsberry Analysis of Ciprofloxacin Activity against Streptococcus pneumoniae after 10 Years of Use in the United States Antimicrob. Agents Chemother., September 1, 2000; 44(9): 2521 - 2524. [Abstract] [Full Text]
|
|
|
|
 |
|
 V. A. Luna and M. C. Roberts In-vitro activities of 11 antibiotics against 75 strains of Streptococcus pneumoniae with reduced susceptibilities to penicillin isolated from patients in Washington State J. Antimicrob. Chemother., October 1, 1999; 44(4): 578 - 580. [Full Text] [PDF]
|
|
|
|
|
|
F. Fitoussi, C. Doit, P. Geslin, and E. Bingen Killing Activities of Trovafloxacin Alone and in Combination with beta -Lactam Agents, Rifampin, or Vancomycin against Streptococcus pneumoniae Isolates with Various Susceptibilities to Extended-Spectrum Cephalosporins at Concentrations Clinically Achievable in Cerebrospinal Fluid Antimicrob. Agents Chemother., October 1, 1999; 43(10): 2372 - 2375. [Abstract] [Full Text]
|
|
|
|
|
|
W. Ng, I. Lutsar, L. Wubbel, F. Ghaffar, H. Jafri, G. H. McCracken, and I. R. Friedland Pharmacodynamics of trovafloxacin in a mouse model of cephalosporin-resistant Streptococcus pneumoniae pneumonia J. Antimicrob. Chemother., June 1, 1999; 43(6): 811 - 816. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P.-L. Ho, T.-L. Que, D. N.-C. Tsang, T.-K. Ng, K.-H. Chow, and W.-H. Seto Emergence of Fluoroquinolone Resistance among Multiply Resistant Strains of Streptococcus pneumoniae in Hong Kong Antimicrob. Agents Chemother., May 1, 1999; 43(5): 1310 - 1313. [Abstract] [Full Text]
|
|